0000919956-18-000025.txt : 20180503 0000919956-18-000025.hdr.sgml : 20180503 20180503160755 ACCESSION NUMBER: 0000919956-18-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180503 DATE AS OF CHANGE: 20180503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 18803801 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20180331x10q.htm 2018 Q1 10-Q Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: March 31, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨(do not check if a smaller reporting company)
Smaller reporting company
 
ý
 
 
 
Emerging growth company
 
¨
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
¨


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,451,495
(Outstanding shares of the issuer’s common stock as of April 30, 2018)
 



Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
March 31,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
6,418

 
$
3,524

Receivables, less allowance for doubtful accounts and other contractual allowances of $15,129 and $14,235, respectively
62,212

 
64,929

Other receivables
1,128

 
375

Prepaid expenses and other current assets
3,671

 
3,248

Income tax refundable
569

 
537

Current assets of discontinued operations
20

 
45

Total current assets
74,018

 
72,658

PROPERTY AND EQUIPMENT, at cost
133,754

 
147,549

Less accumulated depreciation and amortization
(78,548
)
 
(78,345
)
Property and equipment, net
55,206

 
69,204

OTHER ASSETS:
 
 
 
Deferred income taxes, net
15,020

 
15,154

Deferred lease and other costs, net
125

 
137

Acquired leasehold interest, net
6,595

 
6,691

Assets held for sale
13,228

 
—

Other noncurrent assets
3,656

 
3,725

Total other assets
38,624

 
25,707

 
$
167,848

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

2


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(continued)
 
 
March 31,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
12,913

 
$
13,065

Trade accounts payable
13,775

 
14,080

Current liabilities of discontinued operations
462

 
461

Accrued expenses:
 
 
 
Payroll and employee benefits
18,890

 
20,013

Self-insurance reserves, current portion
9,134

 
8,792

Other current liabilities
8,859

 
7,856

Total current liabilities
64,033

 
64,267

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net
75,669

 
74,603

Self-insurance reserves, less current portion
13,891

 
13,458

Other noncurrent liabilities
7,880

 
8,779

Total noncurrent liabilities
97,440

 
96,840

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ EQUITY:
 
 
 
Common stock, authorized 20,000 shares, $.01 par value, 6,773 and 6,687 shares issued, and 6,542 and 6,455 shares outstanding, respectively
68

 
67

Treasury stock at cost, 232 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
22,890

 
22,720

Accumulated deficit
(15,000
)
 
(14,534
)
Accumulated other comprehensive income
917

 
709

Total shareholders’ equity
6,375


6,462

 
$
167,848

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

3


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended March 31,
 
2018
 
2017
PATIENT REVENUES, net
$
141,285

 
$
141,500

EXPENSES:
 
 
 
Operating
112,278

 
110,667

Lease and rent expense
13,713

 
13,743

Professional liability
2,775

 
2,670

General and administrative
8,139

 
8,973

Depreciation and amortization
2,881

 
2,487

Total expenses
139,786

 
138,540

OPERATING INCOME
1,499

 
2,960

OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate
—

 
733

Other income
51

 
—

Interest expense, net
(1,669
)
 
(1,483
)
Total other expense
(1,618
)
 
(750
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(119
)
 
2,210

BENEFIT (PROVISION) FOR INCOME TAXES
38

 
(862
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(81
)
 
1,348

LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit of $11 and $9, respectively
(22
)
 
(15
)
NET INCOME (LOSS)
$
(103
)
 
$
1,333

NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(0.01
)
 
$
0.22

Discontinued operations
—

 
—

 
$
(0.01
)
 
$
0.22

Per common share – diluted
 
 
 
Continuing operations
$
(0.01
)
 
$
0.21

Discontinued operations
—

 
—

 
$
(0.01
)
 
$
0.21

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,314

 
6,233

Diluted
6,314

 
6,440

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands and unaudited)
 
 
Three Months Ended March 31,
 
2018
 
2017
NET INCOME (LOSS)
$
(103
)
 
$
1,333

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
322

 
254

Less: reclassification adjustment for amounts recognized in net income
(114
)
 
(117
)
Total other comprehensive income
208

 
137

COMPREHENSIVE INCOME
$
105

 
$
1,470


The accompanying notes are an integral part of these interim consolidated financial statements.

5


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Three Months Ended March 31,
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
$
(103
)
 
$
1,333

Discontinued operations
(22
)
 
(15
)
Income from continuing operations
(81
)
 
1,348

Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
2,881

 
2,487

Provision for doubtful accounts
—

 
1,970

Deferred income tax provision
—

 
354

Provision for self-insured professional liability, net of cash payments
956

 
(83
)
Stock-based compensation
284

 
241

Gain on sale of unconsolidated affiliate
—

 
(733
)
Provision for leases in excess of cash payments
(453
)
 
(91
)
Deferred bonus
—

 
500

Other
140

 
123

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
2,017

 
(6,518
)
Prepaid expenses and other assets
(439
)
 
1,081

Trade accounts payable and accrued expenses
(86
)
 
(1,468
)
Net cash provided by (used in) continuing operations
5,219

 
(789
)
Discontinued operations
(474
)
 
(67
)
Net cash provided by (used in) operating activities
4,745

 
(856
)
CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(2,012
)
 
(2,237
)
Net cash used in continuing operations
(2,012
)
 
(2,237
)
Discontinued operations
—

 
—

Net cash used in investing activities
(2,012
)
 
(2,237
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(4,762
)
 
(9,193
)
Proceeds from issuance of debt
5,651

 
12,567

Financing costs
(132
)
 
(10
)
Issuance and redemption of employee equity awards
(78
)
 
(94
)
Payment of common stock dividends
(350
)
 
(346
)
Payment for preferred stock restructuring
(168
)
 
(163
)
Net cash provided by financing activities
161

 
2,761

Discontinued operations
—

 
—

Net cash provided by financing activities
$
161

 
$
2,761

The accompanying notes are an integral part of these interim consolidated financial statements.

6


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Three Months Ended March 31,
 
2018
 
2017
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
$
2,894

 
$
(332
)
CASH AND CASH EQUIVALENTS, beginning of period
3,524

 
4,263

CASH AND CASH EQUIVALENTS, end of period
$
6,418

 
$
3,931

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest
$
1,432

 
$
1,231

Cash payments (refunds) of income taxes
$
(16
)
 
$
6

The accompanying notes are an integral part of these interim consolidated financial statements.

7


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2018 AND 2017
(Dollars and shares in thousands, except per share data)
(Unaudited)

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized an additional gain of $733 for the three-month period ended March 31, 2017, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the three month periods ended March 31, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2018, and the results of operations and cash flows for the three month periods ended March 31, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended March 31, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

3.
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement

8


of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15,

9


2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 ("SAB No. 118").

4. REVENUE RECOGNITION

On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding states. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless these is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and , therefore, the changes in its estimate of variable consideration better represent and impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

10


The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, since the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606
The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results (dollar amounts in thousands):

 
Three Months Ended March 31, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,285
 
3,463
(256)
3,207
(a)
(b)
$144,492
Accounts Receivable, net
$62,212
 
(256)
(b)
$61,956
Accumulated Deficit
$(15,000)
 
256
(82)
174
(b)
(c)

$(14,826)

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $256.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended March 31,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
63,886

45.2
%
 
$
73,214

50.7
%
 
$
72,873

51.5
%
Medicare
29,751

21.1
%
 
38,139

26.4
%
 
38,011

26.9
%
Managed Care
14,212

10.1
%
 
12,092

8.4
%
 
10,806

7.6
%
Private Pay and other
33,436

23.6
%
 
21,047

14.5
%
 
19,810

14.0
%
Total
$
141,285

100.0
%
 
$
144,492

100.0
%
 
$
141,500

100.0
%


(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.

  
5.
LONG-TERM DEBT AND INTEREST RATE SWAP

11


The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $73,000 as of March 31, 2018, consisting of $64,000 on the term loan facility with an interest rate of 5.75% and $9,000 on the acquisition loan facility with an interest rate of 6.5%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of March 31, 2018, the Company had $16,000 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,620 outstanding as of March 31, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $39,468 the balance available for borrowing under the Amended Revolver was $9,848 at March 31, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,355 as of March 31, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $492

12


at March 31, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at March 31, 2018 is $335 net of the income tax provision of $157. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.



13


6.    COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $20,536 as of March 31, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of March 31, 2018, the Company is engaged in 73 professional liability lawsuits. Ten lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $1,093 and $2,071 for the three months ended March 31, 2018 and 2017, respectively.
The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" on the Consolidated Balance Sheet. As of March 31, 2018 there are no estimated insurance recovery receivables.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

14


Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. The investigation relates to the Company’s practices and policies for rehabilitation, and other services, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July 1, 2008 through March 31, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $802 at March 31, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,061 as of March 31, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of March 31, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,687 at March 31, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.

7.
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation
rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the three months ended March 31, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
212

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.88

Outstanding, March 31, 2018
227

 
$
6.56

 
 
 
 
Exercisable, March 31, 2018
207

 
$
6.40


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(79
)
 
10.27

Cancelled
(1
)
 
10.17

Outstanding, March 31, 2018
175

 
$
8.85


15


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(17
)
 
8.91

Outstanding, March 31, 2018
44

 
$
9.30


The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.88
 
$
9.32

 
60

 
$
56

 
40

 
$
19

$2.37 to $6.21
 
$
5.56

 
167

 
$
741

 
167

 
$
741

 
 
 
 
227

 
 
 
207

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $284 and $241 in the three month periods ended March 31, 2018 and 2017, respectively.

8.
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss)
 
 
 
Income (loss) from continuing operations
$
(81
)
 
$
1,348

Loss from discontinued operations, net of income taxes
(22
)
 
(15
)
Net income (loss)
$
(103
)
 
$
1,333

 

16


 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss) per common share:
 
 
 
Per common share – basic
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.22

Loss from discontinued operations
—

 
—

Net income (loss) per common share – basic
$
(0.01
)
 
$
0.22

Per common share – diluted
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.21

Loss from discontinued operations
—

 
—

Net income (loss) per common share – diluted
$
(0.01
)
 
$
0.21

Weighted Average Common Shares Outstanding:
 
 
 
Basic
6,314

 
6,233

Diluted
6,314

 
6,440

The effects of 30 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2018 and 2017, respectively, because these securities would have been anti-dilutive.
9.
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:

 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675



17


2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,228. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733 in the first quarter of 2017, related to the final liquidation of remaining net assets affiliated with the partnership.


18


ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted living and residential beds.
Key Performance Metrics
Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living services) from all payor sources are receiving services as the skilled nursing facilities for any given period.
Average rate per day. Average rate per day is the revenue by primary payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.
Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care as a percentage of total number of patient days.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in these initiatives and expect to continue to build on these improvements. In light of challenges facing the industry and the Company specifically, including the unresolved governmental investigation, we believe that now is not the time to attempt to engage in a company-wide strategic transaction.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended March 31, 2018 and 2017 was 16.1% and 15.7%, respectively. The graph below illustrates our success with increasing our average Medicare rate per day:
medicarerateperday.jpg



19


Utilizing Electronic Medical Records to improve Medicaid acuity capture:
As another part of our strategic operating initiatives, we successfully completed a full implementation of EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. We completed the implementation on time and under budget, and since implementation, have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery. The graph below illustrates our success with increasing our average Medicaid rate per day since implementation:
medicaidrateperday.jpg
Completing strategic acquisitions and dispositions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and dispositions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing geographic areas of operation. We expect to announce additional development projects in the near future.
Effective July 1, 2017, we acquired a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750,000, pursuant to an Asset Purchase Agreement with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC. This transaction is further discussed in Note 9 "Business Development and Other Significant Transactions" to the interim consolidated financial statements.
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,228. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we ceased operations at our Carthage, Mississippi, facility in September 2017 thus terminating our lease agreements with the lessor. This transaction was not reported as discontinued operations as described in Note 9 to the interim consolidated financial statements.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2017 Annual Report on Form 10-K.

20




21


Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by primary payor source for the periods presented (dollar amounts in thousands). The difference between 2018 revenue reported below and in the accompanying statements of operations is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
 
Three Months Ended March 31,
 
2018
 
2018
 
2017
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
63,886

45.2
%
 
$
73,214

50.7
%
 
$
72,873

51.5
%
Medicare
29,751

21.1
%
 
38,139

26.4
%
 
38,011

26.9
%
Managed Care
14,212

10.1
%
 
12,092

8.4
%
 
10,806

7.6
%
Private Pay and other
33,436

23.6
%
 
21,047

14.5
%
 
19,810

14.0
%
Total
$
141,285

100.0
%
 
$
144,492

100.0
%
 
$
141,500

100.0
%

The following table sets forth average daily skilled nursing census by primary payor source for our continuing operations for the periods presented: 
 
Three Months Ended March 31,
 
2018
2017
Medicaid
4,589

 
67.9
%
 
4,649

 
68.7
%
Medicare
783

 
11.6

 
792

 
11.7

Managed Care
303

 
4.5

 
273

 
4.0

Private Pay and other
1,081

 
16.0

 
1,056

 
15.6

Total
6,756

 
100.0
%
 
6,770

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to regulation by numerous federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.
In recent years, the U.S. Congress and some state legislatures have considered and enacted significant legislation concerning health care and health insurance. The most prominent of these efforts, The Affordable Care Act affects how health care services are covered, delivered and reimbursed. As currently structured, the Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large

22


employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. Reforms that we believe may have a material impact on the long-term care industry and on our business include, among others, possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. However, there is considerable uncertainty regarding the future of the Affordable Care Act. The Presidential administration and certain members of Congress have expressed their intent to repeal or make significant changes to the law, its implementation or its interpretation. For example, in 2017, Congress eliminated the financial penalty associated with the individual mandate, effective January 1, 2019.
Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidating billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown. The process for defining bundled services has not been fully determined by CMS and therefore is subject to change during the rule making process.
On April 27, 2018, CMS published a proposed rule outlining Medicare payment rates for skilled nursing facilities that, if approved as proposed, would be effective October 1, 2018. CMS proposes that the SNF market basket be updated by 2.4% as required by the Bipartisan Budget Act of 2018. Additionally, the proposed rule includes proposals relating to the SNF Quality Reporting Program and the Skilled Nursing Facility Value-Based Purchasing ("VBP") Program, that, as proposed, would affect Medicare payment beginning on October 1, 2018. CMS is also proposing a new Patient-Driven Payment Model ("PDPM") to replace the existing case-mix methodology, the Resource Utilization Group ("RUG-IV") model. CMS indicates that the proposed PDPM is expected to better account for patient characteristics by relating payment to patients' conditions and clinical needs rather than on volume-based services and reduce the administrative burden on providers. If finalized as proposed, the PDPM would be effective October 1, 2019 and implemented in lieu of the previously proposed Resident Classification System, Version I ("RCS-I").. CMS proposes to use a budget neutrality factor to satisfy the requirement that PDPM be budget neutral relative to RUG-IV, given that CMS states that it intends for the new model to not to change the aggregate amount of Medicare payments to SNFs, but to more accurately reflect resource utilization without incentivizing inappropriate care delivery. The proposed rule is currently open for public comment, after which the details of the final rule may vary from those summarized above.

Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of March 31, 2018, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
103,665

 
$
17,895

 
$
85,735

 
$
35

 
$
—

Settlement obligations (2)
949

 
949

 
—

 
—

 
—

Elimination of Preferred Stock Conversion feature (3)
343

 
343

 
—

 
—

 
—

Operating leases (4)
1,059,914

 
58,342

 
120,238

 
123,714

 
757,620

Required capital expenditures under operating leases (5)
11,347

 
1,205

 
2,410

 
2,410

 
5,322

Total
$
1,176,218

 
$
78,734

 
$
208,383

 
$
126,159

 
$
762,942

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations. Our long-term debt obligations increased $0.2 million between December 31, 2017 and March 31, 2018, which is related to assumption of operation for the Golden Living centers and purchase of the center in Selma, Alabama. See Note 5, "Long-Term Debt and Interest Rate Swap," to the interim consolidated financial statements included in this report for additional information.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Payments to Omega Health Investors ("Omega"), from which we lease 35 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.

23


(4)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted. Our operating lease obligations decreased $5.7 million between December 31, 2017 and March 31, 2018.
(5)
Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $0.6 million between December 31, 2017 and March 31, 2018.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.9 million as of March 31, 2018. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on March 31, 2018, the potential contingent liability for the repurchase of the equity grants is $0.2 million.
Results of Operations
The following tables present the unaudited interim consolidated statements of operations and related data for the three month periods ended March 31, 2018 and 2017:
 
(in thousands)
Three Months Ended March 31,
 
2018
 
2017
 
Change
 
%
PATIENT REVENUES, net
$
141,285

 
$
141,500

 
$
(215
)
 
(0.2
)%
EXPENSES:
 
 
 
 
 
 
 
Operating
112,278

 
110,667

 
1,611

 
1.5
 %
Lease and rent expense
13,713

 
13,743

 
(30
)
 
(0.2
)%
Professional liability
2,775

 
2,670

 
105

 
3.9
 %
General and administrative
8,139

 
8,973

 
(834
)
 
(9.3
)%
Depreciation and amortization
2,881

 
2,487

 
394

 
15.8
 %
Total expenses
139,786

 
138,540

 
1,246

 
0.9
 %
OPERATING INCOME
1,499

 
2,960

 
(1,461
)
 
(49.4
)%
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate
—

 
733

 
(733
)
 
(100.0
)%
Other income
51

 
—

 
51

 
100.0
 %
Interest expense, net
(1,669
)
 
(1,483
)
 
(186
)
 
(12.5
)%
 
(1,618
)
 
(750
)
 
(868
)
 
(115.7
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(119
)
 
2,210

 
(2,329
)
 
(105.4
)%
BENEFIT (PROVISION) FOR INCOME TAXES
38

 
(862
)
 
900

 
104.4
 %
INCOME FROM CONTINUING OPERATIONS
$
(81
)
 
$
1,348

 
$
(1,429
)
 
(106.0
)%



24


Percentage of Net Revenues
Three Months Ended March 31,
 
2018
 
2017
PATIENT REVENUES, net
100.0
 %
 
100.0
%
EXPENSES:
 
 
 
Operating
79.5

 
78.2

Lease and rent expense
9.7

 
9.7

Professional liability
2.0

 
1.9

General and administrative
5.8

 
6.3

Depreciation and amortization
2.0

 
1.8

Total expenses
99.0

 
97.9

OPERATING INCOME
1.0

 
2.1

OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate
—

 
0.5

Other income
—

 
—

Interest expense, net
(1.2
)
 
(1.0
)
 
(1.2
)
 
(0.5
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(0.2
)
 
1.6

BENEFIT (PROVISION) FOR INCOME TAXES
—

 
(0.6
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(0.2
)%
 
1.0
%

25


Three Months Ended March 31, 2018 Compared With Three Months Ended March 31, 2017
Patient Revenues
Patient revenues were $141.3 million and $141.5 million for the three months ended March 31, 2018 and 2017, respectively, a decrease of $(0.2) million. The following summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Three Months Ended March 31,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store revenue
$
138,938

 
$
142,145

 
$
141,500

 
$
645

2017 acquisition revenue
2,347

 
2,347

 
—

 
2,347

Total revenue
$
141,285

 
$
144,492

 
$
141,500

 
$
2,992

The difference between patient revenues for the first quarter of 2018 is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
The overall increase in revenues as adjusted to legacy GAAP of $3.0 million is primarily attributable to revenue contributions from the acquisition of the Park Place operations during the first quarter of 2018 of $2.3 million.
On a same-store center basis, the average Medicare and Medicaid rate per patient day for the first quarter of 2018 increased compared to the first quarter of 2017, resulting in increases in revenue of $0.3 million and $1.1 million, respectively, or 0.9% and 1.5%, respectively. Our same-store Medicare, Medicaid and Private average daily census for the first quarter of 2018 decreased $0.5 million, $0.8 million and $0.4 million, or 1.7%, 1.1% and 3.4%, respectively. Conversely our Managed Care average daily census for the first quarter of 2018 increased $0.9 million or 9.9%.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended March 31,
 
 
 
2018
 
 
 
2017
 
 
Skilled nursing occupancy
79.9
%
 
 
 
80.1
%
 
 
As a percent of total census:
 
 
 
 
 
 
 
Medicare census
11.6
%
 
 
 
11.7
%
 
 
Medicaid census
67.9
%
 
 
 
68.7
%
 
 
Managed Care census
4.5
%
 
 
 
4.0
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
26.4
%
 
 
 
26.9
%
 
 
Medicaid revenues
50.7
%
 
 
 
51.5
%
 
 
Managed Care revenues
8.4
%
 
 
 
7.6
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
455.72

 
  
 
$
451.26

 
 
Medicaid
$
176.78

 
  
 
$
173.75

 
 
Managed Care
$
391.96

 
  
 
$
381.54

 
 

26


Operating Expense
Operating expense increased in the first quarter of 2018 to $112.3 million as compared to $110.7 million in the first quarter of 2017. Operating expense increased as a percentage of revenue at 79.5% for the first quarter of 2018 as compared to 78.2% for the first quarter of 2017. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Three Months Ended March 31,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store operating expense
$
110,709

 
$
114,172

 
$
110,667

 
$
3,505

2017 acquisition expense
1,569

 
1,569

 
—

 
1,569

Total expense
$
112,278

 
$
115,741

 
$
110,667

 
$
5,074

The overall increase in operating expense of $5.1 million is partially attributable to the acquisition of the Park Place operations during the first quarter of 2018 of $1.6 million.
On a same-store center basis, operating expenses slightly increased by $3.5 million, which is attributable to unfavorable variances in provider taxes and salaries and related taxes of $2.3 million and $2.1 million, respectively, in first quarter of 2018 compared to the first quarter of 2017. The change in provider taxes is due to the $2.2 million refund from the state of Kentucky during the first quarter of 2017. Conversely our same-store health insurance costs decreased by $0.9 million in first quarter of 2018 compared to the first quarter of 2017.
One of the largest components of operating expenses is wages, which increased to $67.1 million during the first quarter of 2018 as compared to $65.0 million in the first quarter of 2017, which, consistent with above, is due primarily to acquisition activity.
Lease Expense
Lease expense in the first quarter of 2018 remained consisted with the first quarter of 2017 at $13.7 million.
Professional Liability
Professional liability expense was $2.8 million and $2.7 million in the first quarters of 2018 and 2017, respectively. Our cash expenditures for professional liability costs of continuing operations were $1.1 million and $2.1 million for the first quarters of 2018 and 2017, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $8.1 million in the first quarter of 2018 as compared to $9.0 million in the first quarter of 2017. General and administrative expense decreased as a percentage of revenue from 6.3% in 2017 to 5.8% in 2018. The decrease in general and administrative expense is attributable to a decrease in corporate wages and payroll taxes by $0.9 million. The acquisition of 22 centers in the fourth quarter of 2016 resulted in an increase in salary expenses during the first quarter of 2017.
Depreciation and Amortization
Depreciation and amortization expense was approximately $2.9 million in the first quarter of 2018 as compared to $2.5 million in 2017. The increase in depreciation expense relates to the fixed asset acquisition of a center located in Selma, Alabama during the third quarter of 2017.
Interest Expense, Net
Interest expense was $1.7 million in the first quarter of 2018 and $1.5 million in the first quarter of 2017, an increase of $0.2 million. The increase was primarily attributable to the amendment of the term loan facility that occurred in June 2017.
Loss from Continuing Operations before Income Taxes; Loss from Continuing Operations per Common Share
As a result of the above, continuing operations reported a loss of $0.1 million before income taxes for the first quarter of 2018 as compared to income of $2.2 million for the first quarter of 2017. The benefit for income taxes was $0.1 million for the first quarter of 2018, and the provision for income taxes was $0.9 million for the first quarter of 2017. Both basic and diluted loss per common share from continuing operations were $0.01 for the first quarter of 2018 as compared to basic and diluted income per common share from continuing operations of $0.22 and $0.21, respectively, in the first quarter of 2017.

27



Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our use of cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $5.2 million for the three months ended March 31, 2018, compared to net cash used in operating activities of continuing operations of $0.8 million in the same period of 2017. The primary driver of the increase in cash provided by operating activities from continuing operations is due to the timing of accounts receivable collections.
Our cash expenditures related to professional liability claims of continuing operations were $1.1 million and $2.1 million for three months ended March 31, 2018 and 2017, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $2.0 million and $2.2 million for the three months ended in 2018 and 2017, respectively. The cash used for investing activities relates to the purchase of property and equipment at the centers we operate.
Financing activities of continuing operations provided cash of $0.2 million for the three months ended March 31, 2018 compared to cash provided of $2.8 million for the three months ended March 31, 2017. The decrease is primarily due to draws on the Company's revolving credit facility in 2017.

Dividends
On April 26, 2018, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of June 30, 2018, to be paid on July 16, 2018. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC is maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
As of March 31, 2018, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $20.5 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.

28


Capital Resources
As of March 31, 2018, we had $90.3 million of outstanding long-term debt and capital lease obligations. The $90.3 million total includes $1.1 million in capital lease obligations and $16.0 million currently outstanding on the revolving credit facility. The balance of the long-term debt is comprised of $73.2 million owed on our mortgage loan, which includes $64.0 million on the term loan facility, $9.0 million on the acquisition loan facility and $0.2 million notes payable to finance equipment.
On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100.0 million allocated between a $72.5 million Mortgage Loan ("Amended Mortgage Loan") and a $27.5 million Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60 million term loan facility and a $12.5 million acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2.2 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $72.5 million with a five-year maturity through February 26, 2021, and a $27.5 million Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30.0 million. As of March 31, 2018, the interest rate related to the Amended Mortgage Loan was 5.75%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27.5 million in the Amended Revolver to $52.3 million; provided that the maximum revolving facility be reduced to $42.3 million on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52.3 million.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10.0 million to $15.0 million.
Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7.5 million.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of March 31, 2018, the Company had $16.0 million borrowings outstanding under the Amended Revolver compared to $16.0 outstanding as of December 31, 2017. The outstanding borrowings on the revolver primarily compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under the Amended Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $13.6 million outstanding as of March 31, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $39.5 million, the balance available for borrowing under the Amended Revolver was $9.8 million at March 31, 2018.
Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at March 31, 2018.

29


Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
March 31, 2018
Minimum fixed charge coverage ratio
1.01:1.00
 
1.03:1.00
Minimum adjusted EBITDA
$13.0 million
 
$17.9 million
EBITDAR (mortgaged centers)
$10.0 million
 
$16.5 million
Current ratio (as defined in agreement)
1.00:1.00
 
1.30:1.00
As part of the debt agreements entered into in February 2016, we amended our interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries an initial notional amount of $30.0 million. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
Receivables
Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid or other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and financial position.
Accounts receivable attributable to patient services of continuing operations totaled $75.1 million at March 31, 2018 compared to $79.2 million at December 31, 2017, representing approximately 47 days and 49 days revenue in accounts receivable, respectively. The decrease in accounts receivable is due to the timing of accounts receivable payments.
The allowance for doubtful accounts and other contractual allowances was $15.1 million at March 31, 2018 as compared to $14.2 million at December 31, 2017. We continually evaluate the adequacy of our bad debt reserves based on patient mix trends, aging of older balances, payment terms and delays with regard to third-party payors, collateral and deposit resources, as well as other factors. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $13.6 million as of March 31, 2018. Ten of these letters of credit serve as a security deposits for certain center leases, while one was issued in conjunction with the initial funding of our wholly-owned captive insurance company. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:
•
our ability to successfully integrate the operations of our new nursing centers in Alabama, as well as successfully operate all of our centers,

30


•
our ability to increase census at our centers and occupancy rates at our centers,
•
changes in governmental reimbursement,
•
government regulation,
•
the impact of the Affordable Care Act, efforts to repeal or significantly modify the Affordable Care Act, and other health care reform initiatives,
•
any increases in the cost of borrowing under our credit agreements,
•
our ability to comply with covenants contained in those credit agreements,
•
our ability to comply with the terms of our master lease agreements,
•
our ability to renew or extend our leases at or prior to the end of the existing lease terms,
•
the outcome of professional liability lawsuits and claims,
•
our ability to control ultimate professional liability costs,
•
the accuracy of our estimate of our anticipated professional liability expense,
•
the impact of future licensing surveys,
•
the outcome of proceedings alleging violations of state or Federal False Claims Acts,
•
laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,
•
the costs of investing in our business initiatives and development,
•
our ability to control costs,
•
our ability to attract and retain qualified healthcare professionals,
•
changes to our valuation of deferred tax assets,
•
changing economic and competitive conditions,
•
changes in anticipated revenue and cost growth,
•
changes in the anticipated results of operations,
•
the effect of changes in accounting policies as well as others. 
Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2017, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of March 31, 2018, we had outstanding borrowings of approximately $89.2 million, $60.8 million of which was subject to variable interest rates. In connection with our February 2016 financing agreement, we entered into an interest rate swap with an initial notional amount of $30.0 million to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $0.6 million annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of March 31, 2018. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can

31


provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of March 31, 2018, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control Over Financial Reporting
We completed certain changes to our accounting processes related to our implementation of ASC 606, which was adopted on January 1, 2018. We updated our control activities for the adoption of the new accounting standard and the new accounting processes and methodologies established to evaluate contracts with our customers and determine the transaction price to allocate to our performance obligations with those customers as required in the five-step revenue recognition model in ASC 606.
Other than the items described above, there have been no changes in our internal control over financial reporting during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of March 31, 2018, we are engaged in 73 professional liability lawsuits. Ten lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were the subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents and information. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. The investigation relates to the Company’s practices and policies for rehabilitation, and other services, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of these investigations makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.

32


In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company has filed an answer to the amended complaint denying plaintiffs’ allegations and has asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet be certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses do not include any amounts for the pending DOJ investigation or the purported class action against the Arkansas center. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act law could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.
ITEM 1A. RISK FACTORS.
In addition to the other information contained in this Quarterly Report, the risks and uncertainties that we believe could materially affect our business, financial condition or future results and are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 1, 2018. Additional risks and uncertainties which are not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also materially and adversely affect any of our business, financial position or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURE.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.

ITEM 6. EXHIBITS
The following exhibits are filed as part of this report on Form 10-Q.

33


 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 

 
Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
 
 
 

 
Bylaw Second Amendment adopted April 14, 2016.
 
 
 
4.1

 
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 
 

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 

  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document


34


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
May 3, 2018
 
 
 
 
 
 
 
By:
 
/s/ Kelly J. Gill
 
 
 
Kelly J. Gill
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

35
 EX-31.1 2 dvcr-ex311x33118certificat.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, Kelly J. Gill, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 3, 2018
 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer



 EX-31.2 3 dvcr-ex312x33118certificat.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, James R. McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  May 3, 2018
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
Executive Vice President and Chief Financial Officer



 EX-32 4 dvcr-ex32x33118certificati.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED JUNE 30, 2017
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of May 3, 2018.

 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 5 avca-20180331.xml XBRL INSTANCE DOCUMENT 0000919956 2018-01-01 2018-03-31 0000919956 2018-04-30 0000919956 2017-12-31 0000919956 2018-03-31 0000919956 2017-01-01 2017-03-31 0000919956 2017-03-31 0000919956 2016-12-31 0000919956 us-gaap:MaximumMember 2018-03-31 0000919956 us-gaap:MinimumMember 2018-03-31 0000919956 avca:UnnamedPharmacyJointVentureMember 2016-10-01 2016-12-31 0000919956 2016-10-01 2016-12-31 0000919956 avca:UnnamedPharmacyJointVentureMember 2017-01-01 2017-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-03-31 0000919956 avca:PrivatePayAndOtherMember 2018-01-01 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:PrivatePayAndOtherMember 2017-01-01 2017-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:MedicaidMember 2018-01-01 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:MedicaidMember 2017-01-01 2017-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:MedicareMember 2017-01-01 2017-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:ManagedCareMember 2017-01-01 2017-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:ManagedCareMember 2018-01-01 2018-03-31 0000919956 avca:MedicaidMember 2018-01-01 2018-03-31 0000919956 avca:ManagedCareMember 2018-01-01 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:PrivatePayAndOtherMember 2018-01-01 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member avca:MedicareMember 2018-01-01 2018-03-31 0000919956 avca:MedicareMember 2018-01-01 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-03-31 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplicitPriceConcessionOfBadDebtExpenseMember 2018-01-01 2018-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606TaxAdjustmentMember 2018-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-01-01 2018-03-31 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-03-31 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember avca:OmegaHealthcareInvestorsIncMember 2018-03-31 0000919956 avca:AmendedandRestatedCreditAgreementMember 2018-03-31 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-10-03 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:InterestRateSwapMember 2018-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-29 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-01-01 2018-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-03-31 0000919956 avca:SelmaNursingCentersMember us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2017-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2018-03-31 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-12-31 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2018-03-31 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-28 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2018-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-08-01 0000919956 avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 avca:PrefundedDeductiblePolicyMember 2018-01-01 2018-03-31 0000919956 avca:PrefundedDeductiblePolicyMember 2018-03-31 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2018-01-01 2018-03-31 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2013-07-01 2016-02-29 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2018-03-31 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2018-03-31 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2014-10-31 0000919956 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2018-01-01 2018-03-31 0000919956 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-05-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-01-01 2018-03-31 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-05-31 0000919956 us-gaap:EmployeeStockMember 2018-01-01 2018-03-31 0000919956 us-gaap:EmployeeStockMember 2018-03-31 0000919956 us-gaap:EmployeeStockMember 2017-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2017-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-01-01 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-01-01 2018-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-03-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-03-31 0000919956 avca:SelmaNursingCentersMember 2017-12-31 0000919956 avca:SelmaNursingCentersMember 2017-07-01 0000919956 avca:TrendHealthandRehabofCarthageLLCTrendHealthMember 2017-01-01 2017-12-31 0000919956 avca:SelmaNursingCentersMember 2017-01-01 2017-12-31 0000919956 avca:SelmaNursingCentersMember 2017-07-01 2017-07-01 iso4217:USD avca:state avca:lawsuit avca:facility avca:civil_investigative_demand xbrli:pure avca:center iso4217:USD xbrli:shares avca:bed avca:letter_of_credit xbrli:shares avca:investment 6691000 6595000 145000 18 1.01 500000 0 200000 0.03 P25Y 7500000 2 3000000 1000000 2071000 1093000 -157000 8456 103 76 58 18 73 10 1 11 497 320 48 3 -94000 -78000 91000 453000 1.000 0.076 0.515 0.269 0.140 1.000 1.000 0.084 0.507 0.264 0.145 0.101 0.452 0.211 0.236 19000 741000 6.40 10.88 56000 741000 212000 227000 6.64 6.56 9.32 5.56 9.59 9.95 9.30 8.85 207000 15000 0.00 8.14 207000 40000 167000 227000 60000 167000 0 7.52 7.52 30000 P2Y 1061000 false --12-31 Q1 2018 2018-03-31 10-Q 0000919956 6451495 Smaller Reporting Company Diversicare Healthcare Services, Inc. 28355000 30000000 14080000 13775000 62212000 -256000 61956000 64929000 62212000 78345000 78548000 709000 917000 335000 22720000 22890000 241000 284000 14235000 15129000 46000 30000 167569000 167848000 72658000 74018000 25707000 38624000 45000 20000 140000 925000 925000 8750000 9675000 8435000 335000 760000 4263000 3931000 3524000 6418000 -332000 2894000 0 0 0 0 -67000 -474000 680000 380000 0.055 0.055 0.01 0.01 20000000 20000000 6687000 6773000 6455000 6542000 67000 68000 1470000 105000 110667000 112278000 138540000 139786000 0.0475 0.04 0.04 0.065 0.0575 0.0579 P5Y P5Y 137000 125000 2162000 15154000 15020000 354000 0 2487000 2881000 492000 -9000 -11000 0 13228000 0.22 -0.01 0.21 -0.01 20013000 18890000 1366000 733000 733000 0 8973000 8139000 141500000 141285000 -256000 3463000 3207000 144492000 1348000 -81000 2210000 -119000 0.22 -0.01 0.21 -0.01 -15000 -22000 0.00 0.00 0.00 0.00 862000 -38000 6000 -16000 537000 569000 -1468000 -86000 -1081000 439000 6518000 -2017000 -83000 956000 1483000 1669000 1231000 1432000 13620000 167569000 167848000 64267000 64033000 96840000 97440000 461000 462000 1687000 9848000 52250000 39468000 100000000 72500000 12500000 60000000 27500000 10000000 15000000 52250000 42250000 73000000 9000000 64000000 16000000 16000000 74603000 75669000 13065000 12913000 0.0579 3 5000000 500000 500000 20536000 2670000 2775000 2761000 161000 2761000 161000 -2237000 -2012000 -2237000 -2012000 -856000 4745000 -789000 5219000 1333000 -103000 1333000 -103000 -750000 -1618000 10 2960000 1499000 13743000 250000 13713000 3725000 3656000 137000 208000 117000 114000 254000 322000 7856000 8859000 8779000 7880000 -123000 -140000 0 51000 346000 350000 10000 132000 163000 168000 2237000 2012000 3248000 3671000 12567000 5651000 147549000 133754000 69204000 55206000 1970000 0 375000 1128000 9193000 4762000 -14534000 -15000000 256000 -82000 174000 -14826000 141500000 10806000 72873000 38011000 19810000 141285000 144492000 12092000 73214000 38139000 21047000 14212000 63886000 29751000 33436000 8792000 9134000 13458000 13891000 241000 284000 1000 10.17 88000 16000 90000 90000 8.14 8.14 44000 164000 44000 175000 1000 1000 17000 79000 8.91 10.27 350000 150000 8.14 2.37 10.88 6.21 0.33 0.33 0.33 0.33 0.33 0.33 P10Y 0.85 6462000 6375000 232000 232000 2500000 2500000 6440000 6314000 6233000 6314000 802000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a </font><font style="font-family:inherit;font-size:10pt;">$60,000</font><font style="font-family:inherit;font-size:10pt;"> term loan facility and a </font><font style="font-family:inherit;font-size:10pt;">$12,500</font><font style="font-family:inherit;font-size:10pt;"> acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,162</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through February 26, 2021, and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">, respectively. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with an initial notional amount of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan balance was </font><font style="font-family:inherit;font-size:10pt;">$73,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$64,000</font><font style="font-family:inherit;font-size:10pt;"> on the term loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">5.75%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9,000</font><font style="font-family:inherit;font-size:10pt;"> on the acquisition loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the&#160;</font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;">&#160;in the Amended Revolver to&#160;</font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">; provided that the maximum revolving facility be reduced to </font><font style="font-family:inherit;font-size:10pt;">$42,250</font><font style="font-family:inherit;font-size:10pt;"> on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at </font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company&#8217;s letter of credit sublimit from&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than </font><font style="font-family:inherit;font-size:10pt;">1.01</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2018 and for each quarter thereafter. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$16,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the Amended Revolver compared to </font><font style="font-family:inherit;font-size:10pt;">$16,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). Annual fees for letters of credit issued under the Amended Revolver are </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$13,620</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;">$39,468</font><font style="font-family:inherit;font-size:10pt;"> the balance available for borrowing under the Amended Revolver was </font><font style="font-family:inherit;font-size:10pt;">$9,848</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was </font><font style="font-family:inherit;font-size:10pt;">$28,355</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of </font><font style="font-family:inherit;font-size:10pt;">$492</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent assets&#8221; on the Company&#8217;s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$335</font><font style="font-family:inherit;font-size:10pt;"> net of the income tax provision of </font><font style="font-family:inherit;font-size:10pt;">$157</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a </font><font style="font-family:inherit;font-size:10pt;">103</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8,750</font><font style="font-family:inherit;font-size:10pt;">. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;">, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $</font><font style="font-family:inherit;font-size:10pt;">140</font><font style="font-family:inherit;font-size:10pt;"> of acquisition costs and a $</font><font style="font-family:inherit;font-size:10pt;">925</font><font style="font-family:inherit;font-size:10pt;"> recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Assets Held for Sale</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are </font><font style="font-family:inherit;font-size:10pt;">$13,228</font><font style="font-family:inherit;font-size:10pt;">. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Lease Termination</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a </font><font style="font-family:inherit;font-size:10pt;">$250</font><font style="font-family:inherit;font-size:10pt;"> cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December&#160;31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Sale of Investment in Unconsolidated Affiliate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> in the first quarter of 2017, related to the final liquidation of remaining net assets affiliated with the partnership.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, the Company recognized an additional gain of </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;">-month period ended March&#160;31, 2017, related to the liquidation of remaining assets affiliated with the partnership. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,492</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">350</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">380</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">680</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the 2010 Plan after May 31, 2027.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">88</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$284</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$241</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,440</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">46</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;">$20,536</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos &amp; Associates, Inc. (&#8220;Merlinos&#8221;) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;">73</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;">Ten</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;">$1,093</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,071</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" on the Consolidated Balance Sheet. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> there are no estimated insurance recovery receivables. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Civil Investigative Demand ("CID") </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. The investigation relates to the Company&#8217;s practices and policies for rehabilitation, and other services, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;">$802</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;">$1,061</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;">$200</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;">$1,687</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;">76</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;">8,456</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;">58</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">497</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted and residential living beds.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 ("SAB No. 118").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 ("SAB No. 118").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">REVENUE RECOGNITION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding states. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless these is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and , therefore, the changes in its estimate of variable consideration better represent and impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, since the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Statement Impact of Adopting ASC 606</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results (dollar amounts in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient Revenues, net</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$141,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,463</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(256</font><font style="font-family:inherit;font-size:10pt;">)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$144,492</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts Receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$62,212</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(256)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$61,956</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated Deficit</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$(15,000)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(82)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(c)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$(14,826)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax adjustment for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$256</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,492</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding states. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless these is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and , therefore, the changes in its estimate of variable consideration better represent and impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, since the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,440</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results (dollar amounts in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient Revenues, net</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$141,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,463</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(256</font><font style="font-family:inherit;font-size:10pt;">)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$144,492</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts Receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$62,212</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(256)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$61,956</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated Deficit</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$(15,000)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(82)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(c)</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$(14,826)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax adjustment for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$256</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> EX-101.SCH 6 avca-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 avca-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 avca-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 avca-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue from Contract with Customer [Abstract] REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Income Statement [Abstract] PATIENT REVENUES, net Health Care Organization, Revenue Net of Patient Service Revenue Provisions EXPENSES: Costs and Expenses [Abstract] Operating Cost of Services Lease and rent expense Operating Leases, Rent Expense, Net Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Total expenses Costs and Expenses OPERATING INCOME Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Gain on sale of investment in unconsolidated affiliate Equity Method Investment, Realized Gain (Loss) on Disposal Other income Other Nonoperating Income Interest expense, net Interest Expense Total other expense Nonoperating Income (Expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest BENEFIT (PROVISION) FOR INCOME TAXES Income Tax Expense (Benefit) INCOME (LOSS) FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent LOSS FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net of tax benefit of $11 and $9, respectively Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent NET INCOME (LOSS) Net Income (Loss) Attributable to Parent NET INCOME (LOSS) PER COMMON SHARE: Earnings Per Share [Abstract] Per common share – basic Earnings Per Share, Basic [Abstract] Per common share – basic, Continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Per common share – basic, Discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) per common share – basic (dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Per common share – diluted, Continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Per common share – diluted, Discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) per common share – diluted (dollars per share) Earnings Per Share, Diluted COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Business Combinations [Abstract] Schedule of allocation for net assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Business Combination Disclosure [Text Block] Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Health Care Organizations [Abstract] COMMITMENTS AND CONTINGENCIES Malpractice Loss Contingency Disclosure [Text Block] Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Omega Healthcare Investors Inc Omega Healthcare Investors Inc [Member] Omega Healthcare Investors Inc [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Mortgage term loan Mortgage Term Loan [Member] Mortgage Term Loan [Member] Acquisition loan facility Mortgage Revolving Credit Facility [Member] Mortgage Revolving Credit Facility [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Credit agreement Line of Credit [Member] Mortgage loan Mortgages [Member] Amended revolver Revolving Credit Facility [Member] Letter of credit Letter of Credit [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amended and restated credit agreement Amended and Restated Credit Agreement [Member] Amended and Restated Credit Agreement [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Interest rate swap Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loan acquisition costs Debt Issuance Costs, Gross Term of agreements Debt Instrument, Term Period of amortization Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Interest rate percentage Debt Instrument, Basis Spread on Variable Rate Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Notional amount of interest rate derivatives Derivative, Notional Amount Amended mortgage loan balance Loans Payable Number of owned nursing centers to secure Amended Mortgage Loan Debt Instrument, Collateral, Number Of Owned Nursing Centers Debt Instrument, Collateral, Number Of Owned Nursing Centers Increase to credit facility limit Line of Credit Facility, Terms, Maximum Increase in Capacity Line of Credit Facility, Terms, Maximum Increase in Capacity Fixed charge coverage ratio Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Borrowings outstanding Long-term Debt Annual fees for letters of credit issued under Revolver (as a percentage) Line of Credit Facility, Fee Percentage on Amount Outstanding Line of Credit Facility, Fee Percentage on Amount Outstanding Number of letters of credit Number of Letters of Credit Number of Letters of Credit Letters of credit security deposit for a lease Letters of Credit Outstanding, Amount Balance available for borrowing under revolving credit center Line of Credit Facility, Current Borrowing Capacity Annual fixed rate percentage Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Net asset based on interest rate swap valuation model Derivative Asset Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Income tax benefit, interest rate swap Net Income Tax Benefit Net income tax benefit. Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Trend Health and Rehab of Carthage, LLC (Trend Health) Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Unnamed pharmacy joint venture Unnamed Pharmacy Joint Venture [Member] Unnamed Pharmacy Joint Venture [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Selma Nursing Centers Selma Nursing Centers [Member] Selma Nursing Centers [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Purchase Price Business Combination, Consideration Transferred Business acquisition, acquisition expenses Business Acquisition, Transaction Costs Gain on bargain purchase Business Combination, Bargain Purchase, Gain Recognized, Amount Number of skilled nursing facilities classified as held for sale Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Noncurrent Cash termination payment Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, beginning (share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Dividend Equivalents (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding, ending (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, beginning (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding, ending (dollars per share) Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Patient Revenues, net Accounts Receivable, net Accounts Receivable, Net Accumulated Deficit Retained Earnings (Accumulated Deficit) Gain on bargain purchase Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Building Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Furniture, Fixtures and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Discontinued operations Income from continuing operations Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax provision Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Stock-based compensation Share-based Compensation Gain on sale of unconsolidated affiliate Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Deferred bonus Deferred Compensation, Bonus Deferred Compensation, Bonus Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by (used in) continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest Interest Paid, Net Cash payments (refunds) of income taxes Income Taxes Paid, Net Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS Nature of Operations [Text Block] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Unfavorable regulatory action Unfavorable Regulatory Action [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Potential violations of false claims act Potential Violations of False Claims Act [Member] Potential Violations of False Claims Act [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Malpractice insurance annual sublimit per center Malpractice Insurance, Annual Sublimit Per Center Malpractice Insurance, Annual Sublimit Per Center Aggregate policy limit Malpractice Insurance, Annual Coverage Limit Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Number of facilities Loss Contingency, Number of Facilities Loss Contingency, Number of Facilities Number of civil investigative demands received Loss Contingency, New Claims Filed, Number Other Insurance Other Insurance Industry Disclosures [Abstract] Insurance policy coverage limits per claim Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Net income (loss) Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Loss from discontinued operations, net of income taxes Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Income (loss) from continuing operations (dollars per share) Loss from discontinued operations (dollars per share) Income (loss) from continuing operations (dollars per share) Loss from discontinued operations (dollars per share) Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accounting Policies [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Statement of Financial Position [Abstract] Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Statement of Comprehensive Income [Abstract] NET INCOME (LOSS) OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Medicaid Medicaid [Member] Medicaid [Member] Medicare Medicare [Member] Medicare [Member] Managed Care Managed Care [Member] Managed Care [Member] Private Pay and other Private Pay And Other [Member] Private Pay And Other [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total revenues Revenue from Contract with Customer, Including Assessed Tax Total revenues, as a percent Revenue From Contract With Customer, Including Assessed Tax, Percentage Revenue From Contract With Customer, Including Assessed Tax, Percentage Antidilutive shares excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Restricted Stock Restricted Stock [Member] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] First anniversary of grant date Share-based Compensation Award, Tranche One [Member] Second anniversary of grant date Share-based Compensation Award, Tranche Two [Member] Third anniversary of grant date Share-based Compensation Award, Tranche Three [Member] Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Shares authorized under the plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares reserved for future issuance (shares) Common Stock, Capital Shares Reserved for Future Issuance Grant of restricted common stock (shares) Vesting percentage of awards Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Share-based compensation expense Allocated Share-based Compensation Expense Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $8.14 to $10.88 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Range of exercise prices, minimum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of exercise prices, maximum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted average exercise prices (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Grants outstanding (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic value - grants outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants exercisable (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic value - grants exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Receivables, less allowance for doubtful accounts and other contractual allowances of $15,129 and $14,235, respectively Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Deferred income taxes, net Deferred Income Tax Assets, Net Deferred lease and other costs, net Deferred Costs Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Other noncurrent assets Other Assets, Noncurrent Total other assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net Long-term Debt and Capital Lease Obligations Self-insurance reserves, less current portion Self Insurance Reserve, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Common stock, authorized 20,000 shares, $.01 par value, 6,773 and 6,687 shares issued, and 6,542 and 6,455 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Accumulated other comprehensive income Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted and residential living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds Consolidation Consolidation, Policy [Policy Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Number of equity method investments sold Number of Equity Method Investments Sold Number of Equity Method Investments Sold Summarized activity of equity compensation plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of summarized activity of Restricted Share Units Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of summarized information regarding stock options and SOSAR grants outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning (shares) Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Expired or cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Outstanding, ending (shares) Exercisable (shares) Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning (dollars per share) Granted (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, ending (dollars per share) Exercisable, weighted average exercise price (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Tax benefit, effect on operating loss Discontinued Operation, Tax Effect of Discontinued Operation LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] EX-101.PRE 10 avca-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 medicaidrateperday.jpg begin 644 medicaidrateperday.jpg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end GRAPHIC 12 medicarerateperday.jpg begin 644 medicarerateperday.jpg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htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2018
Apr. 30, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Amendment Flag false  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   6,451,495
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash and cash equivalents $ 6,418 $ 3,524
Receivables, less allowance for doubtful accounts and other contractual allowances of $15,129 and $14,235, respectively 62,212 64,929
Other receivables 1,128 375
Prepaid expenses and other current assets 3,671 3,248
Income tax refundable 569 537
Current assets of discontinued operations 20 45
Total current assets 74,018 72,658
PROPERTY AND EQUIPMENT, at cost 133,754 147,549
Less accumulated depreciation and amortization (78,548) (78,345)
Property and equipment, net 55,206 69,204
OTHER ASSETS:    
Deferred income taxes, net 15,020 15,154
Deferred lease and other costs, net 125 137
Acquired leasehold interest, net 6,595 6,691
Assets held for sale 13,228 0
Other noncurrent assets 3,656 3,725
Total other assets 38,624 25,707
Total assets 167,848 167,569
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations 12,913 13,065
Trade accounts payable 13,775 14,080
Current liabilities of discontinued operations 462 461
Accrued expenses:    
Payroll and employee benefits 18,890 20,013
Self-insurance reserves, current portion 9,134 8,792
Other current liabilities 8,859 7,856
Total current liabilities 64,033 64,267
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net 75,669 74,603
Self-insurance reserves, less current portion 13,891 13,458
Other noncurrent liabilities 7,880 8,779
Total noncurrent liabilities 97,440 96,840
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:    
Common stock, authorized 20,000 shares, $.01 par value, 6,773 and 6,687 shares issued, and 6,542 and 6,455 shares outstanding, respectively 68 67
Treasury stock at cost, 232 shares of common stock (2,500) (2,500)
Paid-in capital 22,890 22,720
Accumulated deficit (15,000) (14,534)
Accumulated other comprehensive income 917 709
Total shareholders’ equity 6,375 6,462
Total liabilities and shareholder's equity $ 167,848 $ 167,569
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 15,129 $ 14,235
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares issued (shares) 6,773,000 6,687,000
Common stock, shares outstanding (shares) 6,542,000 6,455,000
Treasury stock, shares (shares) 232,000 232,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
PATIENT REVENUES, net $ 141,285 $ 141,500
EXPENSES:    
Operating 112,278 110,667
Lease and rent expense 13,713 13,743
Professional liability 2,775 2,670
General and administrative 8,139 8,973
Depreciation and amortization 2,881 2,487
Total expenses 139,786 138,540
OPERATING INCOME 1,499 2,960
OTHER INCOME (EXPENSE):    
Gain on sale of investment in unconsolidated affiliate 0 733
Other income 51 0
Interest expense, net (1,669) (1,483)
Total other expense (1,618) (750)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (119) 2,210
BENEFIT (PROVISION) FOR INCOME TAXES 38 (862)
INCOME (LOSS) FROM CONTINUING OPERATIONS (81) 1,348
LOSS FROM DISCONTINUED OPERATIONS:    
Operating loss, net of tax benefit of $11 and $9, respectively (22) (15)
NET INCOME (LOSS) $ (103) $ 1,333
Per common share – basic    
Per common share – basic, Continuing operations (dollars per share) $ (0.01) $ 0.22
Per common share – basic, Discontinued operations (dollars per share) 0.00 0.00
Net income (loss) per common share – basic (dollars per share) (0.01) 0.22
Per common share – diluted    
Per common share – diluted, Continuing operations (dollars per share) (0.01) 0.21
Per common share – diluted, Discontinued operations (dollars per share) 0.00 0.00
Net income (loss) per common share – diluted (dollars per share) (0.01) 0.21
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) $ 0.055 $ 0.055
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (shares) 6,314 6,233
Diluted (shares) 6,314 6,440
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Tax benefit, effect on operating loss $ 11 $ 9
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Statement of Comprehensive Income [Abstract]    
NET INCOME (LOSS) $ (103) $ 1,333
OTHER COMPREHENSIVE INCOME:    
Change in fair value of cash flow hedge, net of tax 322 254
Less: reclassification adjustment for amounts recognized in net income (114) (117)
Total other comprehensive income 208 137
COMPREHENSIVE INCOME (LOSS) $ 105 $ 1,470
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET INCOME (LOSS) $ (103) $ 1,333
Discontinued operations (22) (15)
Income from continuing operations (81) 1,348
Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:    
Depreciation and amortization 2,881 2,487
Provision for doubtful accounts 0 1,970
Deferred income tax provision 0 354
Provision for self-insured professional liability, net of cash payments 956 (83)
Stock-based compensation 284 241
Gain on sale of unconsolidated affiliate 0 (733)
Provision for leases in excess of cash payments (453) (91)
Deferred bonus 0 500
Other 140 123
Changes in assets and liabilities affecting operating activities:    
Receivables, net 2,017 (6,518)
Prepaid expenses and other assets (439) 1,081
Trade accounts payable and accrued expenses (86) (1,468)
Net cash provided by (used in) continuing operations 5,219 (789)
Discontinued operations (474) (67)
Net cash provided by (used in) operating activities 4,745 (856)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (2,012) (2,237)
Net cash used in continuing operations (2,012) (2,237)
Discontinued operations 0 0
Net cash used in investing activities (2,012) (2,237)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (4,762) (9,193)
Proceeds from issuance of debt 5,651 12,567
Financing costs (132) (10)
Issuance and redemption of employee equity awards (78) (94)
Payment of common stock dividends (350) (346)
Payment for preferred stock restructuring (168) (163)
Net cash provided by financing activities 161 2,761
Discontinued operations 0 0
Net cash provided by financing activities 161 2,761
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,894 (332)
CASH AND CASH EQUIVALENTS, beginning of period 3,524 4,263
CASH AND CASH EQUIVALENTS, end of period 6,418 3,931
SUPPLEMENTAL INFORMATION:    
Cash payments of interest 1,432 1,231
Cash payments (refunds) of income taxes $ (16) $ 6
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS
 3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
 3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized an additional gain of $733 for the three-month period ended March 31, 2017, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the three month periods ended March 31, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2018, and the results of operations and cash flows for the three month periods ended March 31, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended March 31, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
RECENT ACCOUNTING GUIDANCE
 3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 ("SAB No. 118").
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION
 3 Months Ended
Mar. 31, 2018
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION
REVENUE RECOGNITION

On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding states. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless these is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and , therefore, the changes in its estimate of variable consideration better represent and impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, since the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606
The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results (dollar amounts in thousands):

 
Three Months Ended March 31, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,285
 
3,463
(256)
3,207
(a)
(b)
$144,492
Accounts Receivable, net
$62,212
 
(256)
(b)
$61,956
Accumulated Deficit
$(15,000)
 
256
(82)
174
(b)
(c)

$(14,826)

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $256.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended March 31,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
63,886

45.2
%
 
$
73,214

50.7
%
 
$
72,873

51.5
%
Medicare
29,751

21.1
%
 
38,139

26.4
%
 
38,011

26.9
%
Managed Care
14,212

10.1
%
 
12,092

8.4
%
 
10,806

7.6
%
Private Pay and other
33,436

23.6
%
 
21,047

14.5
%
 
19,810

14.0
%
Total
$
141,285

100.0
%
 
$
144,492

100.0
%
 
$
141,500

100.0
%


(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP
 3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $73,000 as of March 31, 2018, consisting of $64,000 on the term loan facility with an interest rate of 5.75% and $9,000 on the acquisition loan facility with an interest rate of 6.5%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of March 31, 2018, the Company had $16,000 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,620 outstanding as of March 31, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $39,468 the balance available for borrowing under the Amended Revolver was $9,848 at March 31, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,355 as of March 31, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $492 at March 31, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at March 31, 2018 is $335 net of the income tax provision of $157. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2018
Health Care Organizations [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $20,536 as of March 31, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of March 31, 2018, the Company is engaged in 73 professional liability lawsuits. Ten lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $1,093 and $2,071 for the three months ended March 31, 2018 and 2017, respectively.
The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" on the Consolidated Balance Sheet. As of March 31, 2018 there are no estimated insurance recovery receivables.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. The investigation relates to the Company’s practices and policies for rehabilitation, and other services, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July 1, 2008 through March 31, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $802 at March 31, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,061 as of March 31, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of March 31, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,687 at March 31, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the three months ended March 31, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
212

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.88

Outstanding, March 31, 2018
227

 
$
6.56

 
 
 
 
Exercisable, March 31, 2018
207

 
$
6.40


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(79
)
 
10.27

Cancelled
(1
)
 
10.17

Outstanding, March 31, 2018
175

 
$
8.85


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(17
)
 
8.91

Outstanding, March 31, 2018
44

 
$
9.30



The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.88
 
$
9.32

 
60

 
$
56

 
40

 
$
19

$2.37 to $6.21
 
$
5.56

 
167

 
$
741

 
167

 
$
741

 
 
 
 
227

 
 
 
207

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $284 and $241 in the three month periods ended March 31, 2018 and 2017, respectively.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS (LOSS) PER COMMON SHARE
 3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER COMMON SHARE
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss)
 
 
 
Income (loss) from continuing operations
$
(81
)
 
$
1,348

Loss from discontinued operations, net of income taxes
(22
)
 
(15
)
Net income (loss)
$
(103
)
 
$
1,333

 
 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss) per common share:
 
 
 
Per common share – basic
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.22

Loss from discontinued operations
—

 
—

Net income (loss) per common share – basic
$
(0.01
)
 
$
0.22

Per common share – diluted
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.21

Loss from discontinued operations
—

 
—

Net income (loss) per common share – diluted
$
(0.01
)
 
$
0.21

Weighted Average Common Shares Outstanding:
 
 
 
Basic
6,314

 
6,233

Diluted
6,314

 
6,440


The effects of 30 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2018 and 2017, respectively, because these securities would have been anti-dilutive.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
 3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:

 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675


2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,228. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733 in the first quarter of 2017, related to the final liquidation of remaining net assets affiliated with the partnership.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)
 3 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidation
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016.
Basis of Accounting
The interim consolidated financial statements for the three month periods ended March 31, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2018, and the results of operations and cash flows for the three month periods ended March 31, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended March 31, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Recent Accounting Guidance
Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 ("SAB No. 118").
Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding states. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless these is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and , therefore, the changes in its estimate of variable consideration better represent and impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, since the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION (Tables)
 3 Months Ended
Mar. 31, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results (dollar amounts in thousands):

 
Three Months Ended March 31, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,285
 
3,463
(256)
3,207
(a)
(b)
$144,492
Accounts Receivable, net
$62,212
 
(256)
(b)
$61,956
Accumulated Deficit
$(15,000)
 
256
(82)
174
(b)
(c)

$(14,826)

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $256.
Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended March 31,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
63,886

45.2
%
 
$
73,214

50.7
%
 
$
72,873

51.5
%
Medicare
29,751

21.1
%
 
38,139

26.4
%
 
38,011

26.9
%
Managed Care
14,212

10.1
%
 
12,092

8.4
%
 
10,806

7.6
%
Private Pay and other
33,436

23.6
%
 
21,047

14.5
%
 
19,810

14.0
%
Total
$
141,285

100.0
%
 
$
144,492

100.0
%
 
$
141,500

100.0
%


(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summarized activity of equity compensation plans
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
212

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.88

Outstanding, March 31, 2018
227

 
$
6.56

 
 
 
 
Exercisable, March 31, 2018
207

 
$
6.40
Schedule of summarized activity of Restricted Share Units
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(79
)
 
10.27

Cancelled
(1
)
 
10.17

Outstanding, March 31, 2018
175

 
$
8.85


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.52

Vested
(17
)
 
8.91

Outstanding, March 31, 2018
44

 
$
9.30
Schedule of summarized information regarding stock options and SOSAR grants outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.88
 
$
9.32

 
60

 
$
56

 
40

 
$
19

$2.37 to $6.21
 
$
5.56

 
167

 
$
741

 
167

 
$
741

 
 
 
 
227

 
 
 
207

 
 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS (LOSS) PER COMMON SHARE (Tables)
 3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss)
 
 
 
Income (loss) from continuing operations
$
(81
)
 
$
1,348

Loss from discontinued operations, net of income taxes
(22
)
 
(15
)
Net income (loss)
$
(103
)
 
$
1,333

 
 
Three Months Ended March 31,
 
2018
 
2017
Net income (loss) per common share:
 
 
 
Per common share – basic
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.22

Loss from discontinued operations
—

 
—

Net income (loss) per common share – basic
$
(0.01
)
 
$
0.22

Per common share – diluted
 
 
 
Income (loss) from continuing operations
$
(0.01
)
 
$
0.21

Loss from discontinued operations
—

 
—

Net income (loss) per common share – diluted
$
(0.01
)
 
$
0.21

Weighted Average Common Shares Outstanding:
 
 
 
Basic
6,314

 
6,233

Diluted
6,314

 
6,440
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables)
 3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Schedule of allocation for net assets acquired
The allocation of the purchase price to the net assets acquired is as follows:

 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS (Details)
Mar. 31, 2018
state
center
bed
Accounting Policies [Line Items]  
Number of states in which entity operates | state 10
Number of nursing centers | center 76
Number of licensed nursing beds 8,456
Number of nursing center facilities owned | center 18
Number of nursing center facilities leased | center 58
Number of licensed assisted and residential living beds 497
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 48
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
investment
Schedule of Equity Method Investments [Line Items]      
Number of equity method investments sold | investment     1
Gain on sale of investment in unconsolidated affiliate $ 0 $ 733  
Unnamed pharmacy joint venture      
Schedule of Equity Method Investments [Line Items]      
Gain on sale of investment in unconsolidated affiliate   $ 733 $ 1,366
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION - Adjustments to Operating Results (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Patient Revenues, net $ 141,285 $ 141,500  
Accounts Receivable, net 62,212    
Accumulated Deficit (15,000)   $ (14,534)
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense | Accounting Standards Update 2014-09      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Patient Revenues, net 3,463    
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation | Accounting Standards Update 2014-09      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Patient Revenues, net (256)    
Accumulated Deficit 256    
Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment | Accounting Standards Update 2014-09      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Accumulated Deficit (82)    
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Patient Revenues, net 3,207    
Accounts Receivable, net (256)    
Accumulated Deficit 174    
Calculated under Revenue Guidance in Effect before Topic 606      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Patient Revenues, net 144,492    
Accounts Receivable, net 61,956    
Accumulated Deficit $ (14,826)    
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Disaggregation of Revenue [Line Items]    
Total revenues $ 141,285  
Total revenues, as a percent 100.00%  
Medicaid    
Disaggregation of Revenue [Line Items]    
Total revenues $ 63,886  
Total revenues, as a percent 45.20%  
Medicare    
Disaggregation of Revenue [Line Items]    
Total revenues $ 29,751  
Total revenues, as a percent 21.10%  
Managed Care    
Disaggregation of Revenue [Line Items]    
Total revenues $ 14,212  
Total revenues, as a percent 10.10%  
Private Pay and other    
Disaggregation of Revenue [Line Items]    
Total revenues $ 33,436  
Total revenues, as a percent 23.60%  
Calculated under Revenue Guidance in Effect before Topic 606    
Disaggregation of Revenue [Line Items]    
Total revenues $ 144,492 $ 141,500
Total revenues, as a percent 100.00% 100.00%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicaid    
Disaggregation of Revenue [Line Items]    
Total revenues $ 73,214 $ 72,873
Total revenues, as a percent 50.70% 51.50%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicare    
Disaggregation of Revenue [Line Items]    
Total revenues $ 38,139 $ 38,011
Total revenues, as a percent 26.40% 26.90%
Calculated under Revenue Guidance in Effect before Topic 606 | Managed Care    
Disaggregation of Revenue [Line Items]    
Total revenues $ 12,092 $ 10,806
Total revenues, as a percent 8.40% 7.60%
Calculated under Revenue Guidance in Effect before Topic 606 | Private Pay and other    
Disaggregation of Revenue [Line Items]    
Total revenues $ 21,047 $ 19,810
Total revenues, as a percent 14.50% 14.00%
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP (Details)
 3 Months Ended
Feb. 26, 2016
USD ($)
center
Mar. 31, 2018
USD ($)
letter_of_credit
Dec. 31, 2017
USD ($)
Aug. 01, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 29, 2016
USD ($)
Dec. 28, 2016
USD ($)
Oct. 03, 2016
USD ($)
Line of Credit Facility [Line Items]                
Accumulated other comprehensive income (loss)   $ 917,000 $ 709,000          
Interest rate swap                
Line of Credit Facility [Line Items]                
Notional amount of interest rate derivatives   $ 28,355,000            
Annual fixed rate percentage   5.79%            
Net asset based on interest rate swap valuation model   $ 492,000            
Accumulated other comprehensive income (loss)   335,000            
Income tax benefit, interest rate swap   $ (157,000)            
Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Loan acquisition costs $ 2,162,000              
Number of letters of credit | letter_of_credit   11            
Credit agreement | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity $ 100,000,000              
Term of agreements 5 years              
Mortgage loan | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity $ 72,500,000              
Term of agreements 5 years              
Period of amortization 25 years              
Amended mortgage loan balance   $ 73,000,000            
Number of owned nursing centers to secure Amended Mortgage Loan | center 18              
Mortgage loan | Amended and restated credit agreement | Interest rate swap                
Line of Credit Facility [Line Items]                
Debt interest rate at period end 5.79%              
Amended revolver | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity $ 27,500,000 $ 39,468,000   $ 42,250,000 $ 52,250,000     $ 52,250,000
Fixed charge coverage ratio   1.01            
Borrowings outstanding   $ 16,000,000 $ 16,000,000          
Balance available for borrowing under revolving credit center   $ 9,848,000            
Amended revolver | Amended and restated credit agreement | LIBOR                
Line of Credit Facility [Line Items]                
Interest rate percentage 4.00%              
Letter of credit | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity           $ 15,000,000 $ 10,000,000  
Annual fees for letters of credit issued under Revolver (as a percentage) 3.00%              
Mortgage term loan | Mortgage loan | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity $ 60,000,000              
Debt interest rate at period end   5.75%            
Amended mortgage loan balance   $ 64,000,000            
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument                
Line of Credit Facility [Line Items]                
Notional amount of interest rate derivatives $ 30,000,000              
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR                
Line of Credit Facility [Line Items]                
Interest rate percentage 4.00%              
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Borrowing capacity $ 12,500,000              
Debt interest rate at period end   6.50%            
Amended mortgage loan balance   $ 9,000,000            
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR                
Line of Credit Facility [Line Items]                
Interest rate percentage 4.75%              
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement                
Line of Credit Facility [Line Items]                
Letters of credit security deposit for a lease   $ 13,620,000            
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Details)
 3 Months Ended 32 Months Ended
Mar. 31, 2018
USD ($)
lawsuit
Mar. 31, 2017
USD ($)
Feb. 29, 2016
civil_investigative_demand
Oct. 31, 2014
facility
Malpractice Insurance [Line Items]        
Number of professional liability lawsuits | lawsuit 73      
Cash expenditures for self-insured professional liability costs $ 1,093,000 $ 2,071,000    
Other Insurance        
Liability for workers compensation claims 802,000      
Workers compensation insurance, non current receivable for excess premiums paid 1,061,000      
Unfavorable regulatory action | Potential violations of false claims act        
Malpractice Insurance [Line Items]        
Number of facilities | facility       2
Number of civil investigative demands received | civil_investigative_demand     3  
Professional malpractice liability insurance        
Malpractice Insurance [Line Items]        
Liability for reported and estimated future claims 20,536,000      
Prefunded deductible policy        
Malpractice Insurance [Line Items]        
Insurance policy coverage limits per claim 500,000      
Other Insurance        
Insurance policy coverage limits per claim 500,000      
Professional liability insurance, annual coverage limit per facility 3,000,000      
Health insurance, maximum self-insured annual amount per individual 200,000      
Liability for reported claims and estimates for incurred but unreported claims 1,687,000      
SHC Risk Carriers, Inc | Professional malpractice liability insurance        
Malpractice Insurance [Line Items]        
Insurance policy coverage limits per claim 500,000      
Malpractice insurance annual sublimit per center 1,000,000      
Aggregate policy limit 5,000,000      
Other Insurance        
Insurance policy coverage limits per claim $ 500,000      
Scheduled for trial or arbitration over next 12 months        
Malpractice Insurance [Line Items]        
Number of professional liability lawsuits | lawsuit 10      
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jun. 30, 2017
May 31, 2017
Jun. 30, 2016
May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation expense $ 284 $ 241        
Restricted Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Grant of restricted common stock (shares) 90,000 88,000        
Restricted Stock | First anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
Restricted Stock | Second anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
Restricted Stock | Third anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
Stock Options and Stock Appreciation Rights (SARs)            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Payment award, expiration period 10 years          
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting percentage of awards 33.00%          
2008 Stock Purchase Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Percentage of quoted market price offering rate 85.00%          
Restriction period 2 years          
Shares authorized under the plan (shares)         350,000 150,000
2010 Long Term Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares reserved for future issuance (shares)     680,000 380,000    
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs)
shares in Thousands
 3 Months Ended
Mar. 31, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding, beginning (shares) | shares 212
Granted (shares) | shares 30
Exercised (shares) | shares 0
Expired or cancelled (shares) | shares (15)
Outstanding, ending (shares) | shares 227
Exercisable (shares) | shares 207
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 6.64
Granted (dollars per share) | $ / shares 8.14
Exercised (dollars per share) | $ / shares 0.00
Expired or cancelled (dollars per share) | $ / shares 10.88
Outstanding, ending (dollars per share) | $ / shares 6.56
Exercisable, weighted average exercise price (dollars per share) | $ / shares $ 6.40
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details)
shares in Thousands
 3 Months Ended
Mar. 31, 2018
$ / shares
shares
Restricted Stock Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning (share) | shares 164
Granted (shares) | shares 90
Dividend Equivalents (shares) | shares 1
Vested (shares) | shares (79)
Cancelled (shares) | shares (1)
Outstanding, ending (shares) | shares 175
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 9.95
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 7.52
Vested (dollars per share) | $ / shares 10.27
Cancelled (dollars per share) | $ / shares 10.17
Outstanding, ending (dollars per share) | $ / shares $ 8.85
Employee Stock  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning (share) | shares 44
Granted (shares) | shares 16
Dividend Equivalents (shares) | shares 1
Vested (shares) | shares (17)
Outstanding, ending (shares) | shares 44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 9.59
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 7.52
Vested (dollars per share) | $ / shares 8.91
Outstanding, ending (dollars per share) | $ / shares $ 9.30
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise prices (dollars per share) $ 6.56 $ 6.64
Grants outstanding (shares) 227  
Grants exercisable (shares) 207  
$8.14 to $10.88    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 8.14  
Range of exercise prices, maximum (dollars per share) 10.88  
Weighted average exercise prices (dollars per share) $ 9.32  
Grants outstanding (shares) 60  
Intrinsic value - grants outstanding $ 56  
Grants exercisable (shares) 40  
Intrinsic value - grants exercisable $ 19  
$2.37 to $6.21    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 2.37  
Range of exercise prices, maximum (dollars per share) 6.21  
Weighted average exercise prices (dollars per share) $ 5.56  
Grants outstanding (shares) 167  
Intrinsic value - grants outstanding $ 741  
Grants exercisable (shares) 167  
Intrinsic value - grants exercisable $ 741  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS (LOSS) PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net income (loss)    
Income (loss) from continuing operations $ (81) $ 1,348
Loss from discontinued operations, net of income taxes (22) (15)
Net income (loss) $ (103) $ 1,333
Per common share – basic    
Income (loss) from continuing operations (dollars per share) $ (0.01) $ 0.22
Loss from discontinued operations (dollars per share) 0.00 0.00
Net income (loss) per common share – basic (dollars per share) (0.01) 0.22
Per common share – diluted    
Income (loss) from continuing operations (dollars per share) (0.01) 0.21
Loss from discontinued operations (dollars per share) 0.00 0.00
Net income (loss) per common share – diluted (dollars per share) $ (0.01) $ 0.21
Weighted Average Common Shares Outstanding:    
Basic (shares) 6,314 6,233
Diluted (shares) 6,314 6,440
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS (LOSS) PER COMMON SHARE - Narrative (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Earnings Per Share [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share (shares) 30 46
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details)
 3 Months Ended 12 Months Ended
Jul. 01, 2017
USD ($)
bed
Mar. 31, 2018
USD ($)
facility
bed
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Business Acquisition [Line Items]            
Number of licensed nursing beds | bed   8,456        
Number of skilled nursing facilities classified as held for sale | facility   3        
Assets held for sale   $ 13,228,000     $ 0  
Cash termination payment   13,713,000 $ 13,743,000      
Gain on sale of investment in unconsolidated affiliate   $ 0 733,000      
Selma Nursing Centers            
Business Acquisition [Line Items]            
Number of licensed nursing beds | bed 103          
Purchase Price $ 8,750,000          
Business acquisition, acquisition expenses         140,000  
Gain on bargain purchase $ 925,000       925,000  
Unnamed pharmacy joint venture            
Business Acquisition [Line Items]            
Gain on sale of investment in unconsolidated affiliate     $ 733,000 $ 1,366,000    
Trend Health and Rehab of Carthage, LLC (Trend Health)            
Business Acquisition [Line Items]            
Cash termination payment         $ 250,000  
Mortgage term loan | Amended and restated credit agreement | Mortgage loan | Selma Nursing Centers            
Business Acquisition [Line Items]            
Increase to credit facility limit           $ 7,500,000
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) - Selma Nursing Centers - USD ($)
$ in Thousands
 12 Months Ended
Jul. 01, 2017
Dec. 31, 2017
Business Acquisition [Line Items]    
Purchase Price $ 8,750  
Gain on bargain purchase 925 $ 925
Assets acquired 9,675  
Building 8,435  
Land 760  
Land Improvements 145  
Furniture, Fixtures and Equipment $ 335  
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 100 219 1 false 43 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperations INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsParenthetical INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveLoss INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 6 false false R7.htm 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlows INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - BUSINESS Sheet http://www.advocatinc.com/role/Business BUSINESS Notes 8 false false R9.htm 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Notes 9 false false R10.htm 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE Sheet http://www.advocatinc.com/role/RecentAccountingGuidance RECENT ACCOUNTING GUIDANCE Notes 10 false false R11.htm 2104100 - Disclosure - REVENUE RECOGNITION Sheet http://www.advocatinc.com/role/RevenueRecognition REVENUE RECOGNITION Notes 11 false false R12.htm 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap LONG-TERM DEBT AND INTEREST RATE SWAP Notes 12 false false R13.htm 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.advocatinc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2107100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.advocatinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 14 false false R15.htm 2108100 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShare EARNINGS (LOSS) PER COMMON SHARE Notes 15 false false R16.htm 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Notes 16 false false R17.htm 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Policies 17 false false R18.htm 2304301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.advocatinc.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.advocatinc.com/role/RevenueRecognition 18 false false R19.htm 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.advocatinc.com/role/StockBasedCompensation 19 false false R20.htm 2308301 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareTables EARNINGS (LOSS) PER COMMON SHARE (Tables) Tables http://www.advocatinc.com/role/EarningsLossPerCommonShare 20 false false R21.htm 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Tables http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions 21 false false R22.htm 2401401 - Disclosure - BUSINESS (Details) Sheet http://www.advocatinc.com/role/BusinessDetails BUSINESS (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 22 false false R23.htm 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsDetails CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies 23 false false R24.htm 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionAdjustmentsToOperatingResultsDetails REVENUE RECOGNITION - Adjustments to Operating Results (Details) Details 24 false false R25.htm 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionDisaggregationOfRevenueDetails REVENUE RECOGNITION - Disaggregation of Revenue (Details) Details 25 false false R26.htm 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapDetails LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Details http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap 26 false false R27.htm 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.advocatinc.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.advocatinc.com/role/CommitmentsAndContingencies 27 false false R28.htm 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 28 false false R29.htm 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfActivityOfEquityCompensationPlansDetails STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Details 29 false false R30.htm 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfRestrictedStockAndRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Details 30 false false R31.htm 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfAwardsOutstandingAndExercisableDetails STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Details 31 false false R32.htm 2408402 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareBasicAndDilutedNetIncomeLossPerCommonShareDetails EARNINGS (LOSS) PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 32 false false R33.htm 2408403 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE - Narrative (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareNarrativeDetails EARNINGS (LOSS) PER COMMON SHARE - Narrative (Details) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 33 false false R34.htm 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsNarrativeDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 34 false false R35.htm 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsScheduleOfAssetsAcquiredDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Details 35 false false All Reports Book All Reports avca-20180331.xml avca-20180331.xsd avca-20180331_cal.xml avca-20180331_def.xml avca-20180331_lab.xml avca-20180331_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 54 0000919956-18-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-18-000025-xbrl.zip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�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end